Scroll To Top
Health

BMS files for FDA approval of protease inhibitor Zrivada

BMS files for FDA approval of protease inhibitor Zrivada

We need your help
Your support makes The Advocate's original LGBTQ+ reporting possible. Become a member today to help us continue this work.

Pharmaceutical company Bristol-Myers Squibb this week applied for Food and Drug Administration approval of its experimental second-generation protease inhibitor Zrivada (atazanavir). The FDA application included data from Phase III clinical trials showing that the once-a-day drug is as effective as other protease inhibitors and does not cause blood lipid levels to rise, a problem common with existing protease drugs. More than 2,400 people have participated in studies of Zrivada, which is currently available through an early-access program for patients who have failed other anti-HIV medications. A decision by the FDA is expected by early summer.

Pride of Broadway Special

From our Sponsors

Most Popular

Latest Stories

Advocate.com Editors